Molecular Cell publishes the Discovery and Characterization of PrimPol, a new Type of Human DNA Polymerase
(Thomson Reuters ONE) -
SYGNIS AG /
Molecular Cell publishes the Discovery and Characterization of PrimPol, a new
Type of Human DNA Polymerase
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* PrimPol is the latest polymerase cloned from the human genome. The enzyme
displays novel properties with great potential for application in the field
of DNA sequencing and amplification.
* The work has been conducted under the direction of Luis Blanco, Professor at
CSIC in Madrid and currently Scientific Advisor to SYGNIS AG.
* PrimPol is one of the most innovative products in its field and its
thermostable version one of the principal products in SYGNIS late-stage
pipeline.
Madrid/Heidelberg, 5 November 2013 - SYGNIS AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03; Prime Standard) today announced that Molecular Cell, one of the
scientific journals in the Molecular Biology field with the highest impact
factor, belonging to the same group that publishes "Cell", has recently
published the paper "PrimPol, an Archaic Primase/Polymerase Operating in Human
Cells".
Prof. Luis Blanco, Research Professor at CSIC (Consejo Superior de
Investigaciones Científicas, Madrid), X-Pol co-founder and currently Scientific
Advisor to SYGNIS AG, is the principal investigator behind the paper, that
describes the discovery and characterization of a new type of DNA polymerase,
named PrimPol, cloned from the human genome.
PrimPol is one of the most innovative discoveries in the Molecular Biology field
and one of the key products in SYGNIS AG's portfolio. Luis Blanco stated: "I am
convinced that this fantastic enzyme will open numerous novel applications in
the field of Molecular Biology, some of them we can only hint at this moment
given the highly innovative potential of its key features".
Key features of this enzyme are its duality as a DNA primase and DNA polymerase,
and its high tolerance to damaged DNA. The primase function of PrimPol allows it
to start reading and copying DNA without the need for providing random primers,
as required by all other commercially available polymerases. Using random
primers can bias the sequencing and amplification results. The polymerase
function of PrimPol displays a high specific activity, being very efficient also
when copying DNA with different lesions.
SYGNIS AG is currently developing a new thermostable version of the enzyme that
will exploit the features described above, offering a distinctive product with
huge potential in the DNA amplification and sequencing field.
The Spanish-German company is proud to point out that the publication of Prof.
Blanco's results in a journal of the impact of Molecular Cell reflects the high
scientific quality and novelty of this discovery. This at the same time implies
a high likelihood of signing a lucrative licensing agreement with a
multinational leader in the field of DNA amplification and next generation
sequencing in the coming months.//
___________
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta(at)sygnis.es
About SYGNIS AG: www.sygnis.com
After the merger in 2012 between X-Pol Biotech, specializing in DNA
amplification and sequencing, and SYGNIS AG, listed in the German Stock Exchange
(Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is
to develop and distribute technologies and products from X-Pol, which has a
commercial product in the DNA amplification segment, QualiPhi(®) and is
currently developing other products in the field of Next Generation Sequencing.
### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS AG may deviate greatly from the
established conclusions or implied predictions contained in such statements.
SYGNIS does not undertake to publicly update or revise these statements in the
light of new information or future results or for any other reason.###
Press Release (PDF):
http://hugin.info/150277/R/1740665/584609.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: SYGNIS AG via Thomson Reuters ONE
[HUG#1740665]
Unternehmensinformation / Kurzprofil:
Datum: 05.11.2013 - 13:46 Uhr
Sprache: Deutsch
News-ID 312900
Anzahl Zeichen: 5909
contact information:
Town:
Heidelberg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Molecular Cell publishes the Discovery and Characterization of PrimPol, a new Type of Human DNA Polymerase"
steht unter der journalistisch-redaktionellen Verantwortung von
SYGNIS AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
